Table 2.

Meta-analyses of AEs not related to SSRIs reported in the included RCTs.

AEs	RCTs (N)	OR [95% CI]	Heterogeneity	Effect model	Overall effect (P-value)
Attempted or actual suicide	3	0.82 [0.23–2.84]	P = 0.52, I2 = 0%	Fixed	P = 0.75
Fall with injury	2	1.74 [0.82–3.71]	P = 0.08, I2 = 66%	Random	P = 0.15
Upper gastrointestinal bleed	3	1.30 [0.72–2.34]	P = 0.98, I2 = 0%	Fixed	P = 0.38
Haemorrhagic stroke	4	1.13 [0.56–2.27]	P = 0.47, I2 = 0%	Fixed	P = 0.73
All bleeding events	4	1.18 [0.84–1.65]	P = 0.84, I2 = 0%	Fixed	P = 0.34
Acute coronary events	4	0.61 [0.36–1.01]	P = 0.79, I2 = 0%	Fixed	P = 0.06
Ischaemic stroke	4	0.93 [0.69–1.25]	P = 0.28, I2 = 21%	Fixed	P = 0.64
All thrombotic events	3	0.76 [0.58–1.00]	P = 0.42, I2 = 0%	Fixed	P = 0.05
Diarrhea	4	1.83 [0.90–3.71]	P = 0.48, I2 = 0%	Fixed	P = 0.09
Any Stroke	3	0.93 [0.71–1.21]	P = 0.24, I2 = 30%	Fixed	P = 0.58
Insomnia	6	0.96 [0.60–1.52]	P = 0.81, I2 = 0%	Fixed	P = 0.86
Abnormal liver function	2	0.54 [0.25–1.17]	P = 0.63, I2 = 0%	Fixed	P = 0.12
Dizziness	3	1.07 [0.47–2.46]	P = 0.38, I2 = 0%	Fixed	P = 0.87
Headache	2	4.23 [0.46–39.26]	P = 0.84, I2 = 0%	Fixed	P = 0.20
Sweating	3	5.29 [0.90–31.15]	P = 0.91, I2 = 0%	Fixed	P = 0.07
Increased appetite	2	3.90 [0.77–19.79]	P = 0.88, I2 = 0%	Fixed	P = 0.10
Palpitation	3	0.97 [0.13–6.99]	P = 0.34, I2 = 0%	Fixed	P = 0.97
Abdominal pain	2	1.73 [0.50–6.00]	P = 0.49, I2 = 0%	Fixed	P = 0.39
Death	8	0.99 [0.80–1.22]	P = 0.58, I2 = 0%	Fixed	P = 0.91
Drowsiness	3	1.55 [0.74–3.27]	P = 0.94, I2 = 0%	Fixed	P = 0.25
Fatigue	2	0.98 [0.37–2.60]	P = 0.52, I2 = 0%	Fixed	P = 0.97
Sexual Dysfunction	3	1.71 [0.73–4.03]	P = 0.73, I2 = 0%	Fixed	P = 0.22
Restlessness	2	3.00 [0.12–77.17]	–	Fixed	P = 0.51
Hyperglycaemia	3	0.73 [0.17–3.10]	P = 0.02, I2 = 83%	Random	P = 0.67
Symptomatic hypoglycaemia	2	1.78 [0.90–3.53]	–	Fixed	P = 0.10

AEs, adverse events; SSRIs, selective serotonin reuptake inhibitors; RCTs, randomized controlled trials; OR, odds ratios; CI, confidence intervals.